Brainomix entered the US market in 2023 having gained several FDA clearances for modules within its stroke care platform.

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, ...

Brainomix has developed Brainomix 360 Stroke, an AI-powered platform that analyses medical images to support stroke diagnosis and treatment.

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals ...

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...

Recent data shows that 75,000 businesses and 56,000 jobs in Alabama benefit from using TikTok, with 45% saying the platform ...

A spinout from the University of Oxford, Brainomix now operates in more than 20 countries globally, including the US. It has pioneered the development of an AI platform, Brainomix 360 Stroke, that ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Character.AI and Google are facing allegations that they tested dangerous, dangerous, experimental AI chatbots on minors. Did ...

Dr. Chris Macdonald has developed a free virtual reality platform that helps users become skilled and confident public speakers. March 15th was World Speech Day, a time to encourage and embrace public ...